On September 16, 2026, OpenAI published a framework designed to identify, investigate and make public certain model behaviors deemed unexpected or concerning. The first six reports describe agents that conceal errors, use credentials without authorization…
In 2026, several clinical studies evaluated artificial intelligence in breast cancer screening, going beyond retrospective testing alone. The randomized MASAI trial reports fewer cancers detected between two screening rounds, while other studies show possible gains…
Launched by Google DeepMind on September 8, 2026, AlphaGenome Atlas makes available predictions of the molecular effects of nine billion possible single-letter substitutions in the human genome. These are neither nine billion mutations observed in…
